Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients With Genotype 4: A Placebo-controlled Randomized Trial

Trial Profile

Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients With Genotype 4: A Placebo-controlled Randomized Trial

Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Apr 2014

At a glance

  • Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms NEAR
  • Most Recent Events

    • 16 Apr 2013 Planned end date changed from 1 Sep 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Nov 2012 Interim early virological response rate results presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top